HEALTHCARE PROFESSIONAL FOLLOW UP FORM VIGILANCE MCN MEDINFO

MGT 810 SELECTED TOPICS IN HEALTHCARE LEADERSHIP AND
2006 Florida Legal Issues Survey Government Benefits and Healthcare
21ST NORTHERN IRELAND HEALTHCARE AWARDS INNOVATIVE DEVELOPMENTS IN THE

23 HEALTHCARE WASTE MANAGEMENT SESSION 23 HEALTHCARE WASTE MANAGEMENT
ADULT CONTINUING HEALTHCARE REFERRAL FORM COMPLETE ALL SECTIONS KEY
AHRQ STATE HEALTHCARE QUALITY IMPROVEMENT WORKSHOP DIABETES CARE QUALITY

Alliance Pharmaceuticals Ltd

Healthcare Professional Follow Up Form


HEALTHCARE PROFESSIONAL FOLLOW UP FORM VIGILANCE MCN  MEDINFO

Vigilance MCN: __________________

Medinfo reference: __________________

Quality Assurance reference: __________________

Please return the completed form to the Vigilance Department



Reporter details:


Name: _________________ Email:_______________________


Address: __________________________________________________________________

Postcode:_________________________

Signature : ________________________

Date: ____________________________

Reporter type:

Doctor Pharmacist Nurse Other: ___________

___

Tel: ______________________ Fax: ______________________



Patient Demographics

Initials

Date of birth

Age

Sex

Height

Weight








Is the patient pregnant? Yes (please provide LMP_______________ and EDD________________) No Unk N/A


Suspected Alliance Products

Name

Batch number

Daily dose

Route

Start Date

Stop Date

Action taken A

Indication


























A Action taken with Alliance products: 1 (Unchanged), 2 (Dose reduced), 3 (Interrupted), 4 (Permanently discontinued), 5 (Unk)


Details of event – please provide final diagnosis if possible

Event(s)

Seriousness Criteria B

Start date

Stop date

Severity C

Outcome D


























B Seriousness Criteria: 1 (Death), 2 (Life threatening), 3 (Significant disability/incapacity), 4 (Hospitalisation)

5 (Congenital anomaly/abnormality), 6 (non-serious)


C Severity: 1 (Mild), 2 (Moderate), 3 (Severe)


D Outcome: 1 (Recovered without sequelae), 2 (Recovered with sequelae), 3 (Recovering), 4 (Not yet recovered), 5 (Died), 6 (Unk)

Concomitant medication

Name

Daily dose

Route

Start Date

Stop Date

Action taken A

Indication

Co-suspect (Y/N)


















































A Action taken with Alliance products: 1 (Unchanged), 2 (Dose reduced), 3 (Interrupted), 4 (Permanently discontinued), 5 (Unk)


P 1 of 2


Medical history / Risk Factor

Condition

Start date


Continuing?

Condition

Start date

Continuing?


























Corrective actions / Therapy used to treat the event(s)

Therapy

Daily dose

Route

Start date

Stop date

Indication




















Relevant tests

Test (& normal range)

Date

Result

( & units)

Test (& normal range)

Date

Result

( & units)


























Causal association


Do you think there is a relationship between the event (s) and Alliance products _______________:



Certain Possible

Probable Unassessable

Unrelated: ______________



Dechallenge


Rechallenge


Yes No Unk N/A



Yes No Unk N/A


Has this event been reported to the Regulatory Authorities? Yes No

Regulatory Authority Reference Number? ________________________

Additional Information

















All the information and Personal Data you share with us will be protected and kept confidential in line with the General Data Protection Regulation (EU 2016/679) for further information please visit: https://alliancepharmaceuticals.com/en-gb/terms-of-use .

P 2 of 2

FM-022-01 v3-0


AKHIL HEALTHCARE PVT LTD NAME OF THE PERSON MR
ALLGEMEINE EINKAUFSBEDINGUNGEN DER GSKGEBRO CONSUMER HEALTHCARE GMBH
APPENDIX 12 UNITED BRISTOL HEALTHCARE NHS TRUST PAYMENT BY


Tags: follow up, healthcare, vigilance, professional, follow, medinfo